Global Biologics CDMO Market is projected to witness a healthy growth rate of 15% to reach $35 billion by 2025 - Increasing VC Fundings, Expanding Pipelines of Cell & Gene Therapies

The significant growth in the biopharmaceutical sales and pipeline and growing complexity of molecules would drive the outsourcing of biologics development and manufacturing services across the product lifecycle. Moreover, the growing number of molecules (recombinant proteins and antibodies) in the pipeline which are being developed by small and virtual biotechs (>60%) who lack in-house manufacturing capabilities and expertise to bring their candidates and resources to market would in turn boost the demand for Biologics CDMO services.

Huge Growth Potential for Upturn in Outsourcing Ratio

The outsourcing ratio in biologics manufacturing is much less compared to that for small molecules, providing ample growth opportunities. With the increasingly complex and rapidly evolving biopharmaceutical market, companies are looking for CDMOs who can provide regulatory leadership and expertise in all stages from early-stage discovery to commercialization. Moreover, latest technologies like viral vector, mRNA, and cell & gene therapy are where demand exceeds supply, and capabilities may not exist even in large biopharmaceutical companies thereby offering wide scope for outsourcing to CDMOs.

Shifting Market Trend Towards Full-service CDMOs/One-stop-shop Model

Large pharmaceutical companies prefer to select a CDMO which also has an early-stage development capabilities, as switching costs are significantly higher once cell lines and processes are established. Due to the complexities intrinsic to biologics development, biopharmaceutical companies look for a full-service CDMO which can handle all services, from cell line development through fill-finish and packaging.

CDMOs are Embracing Digital Manufacturing

CDMOs are increasingly resorting to data-driven techniques to make manufacturing more efficient.

"In time, all CDMOs are likely to go digital. Customer demand for high-quality products and information will cause data-driven manufacturing to become the future norm." -Lead Scientist, Tier 1 CDMO, United States

Geohgraphic Analysis: North America has the Largest Share of Biologics CDMO Market

North America is the largest biologics CDMO market while Asia-Pacific is expected to witness the highest CAGR in the next 5 years, depended on China. To leverage growth opportunities in Asia-Pacific regions, in April 2021, Lonza extended its partnership with Chinese firm Junshi Biosciences to advance and manufacture biologics at its site in Guangzhou, China.

Competitive Landscape Analysis: Biologics CDMO Market

The global biologics CDMO market is characterized by a high degree of fragmentation. Some of the established and emerging companies operating in the biologics CDMO market are Lonza, Catalent, Samsung Biologics, Fujifilm, Wuxi Biologics, and Boehringer Ingelheim. While some of the other promising players are Halix, Cobra Biologics, ABL, Biovian, SK Bioscience, IDT, AGC Biologics, Patheon, Abbvie, Novasep, and Emergent Biosolutions.

Get Detailed Insights on Biologics CDMO Market with a Sample Report PDF @ https://meditechinsights.com/global-biologics-cdmo-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Healthcare IT, MedTech, Medical Devices & Pharma Services.

This release was published on openPR.